Andrew Cheng - May 13, 2021 Form 3 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Director
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Stock symbol
VERA
Transactions as of
May 13, 2021
Transactions value $
$0
Form type
3
Date filed
5/13/2021, 07:16 PM
Next filing
May 18, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VERA Series C Preferred Stock May 13, 2021 Class A Common Stock 17.5K See footnote F1, F2
holding VERA Stock Option (right to buy) May 13, 2021 Class A Common Stock 3.45K $4.40 Direct F3
holding VERA Stock Option (right to buy) May 13, 2021 Class A Common Stock 4.32K $2.32 Direct F4
holding VERA Stock Option (right to buy) May 13, 2021 Class A Common Stock 61.3K $2.90 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series C Preferred Stock is convertible into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and has no expiration date. Upon filing of the Issuer's Restated Certificate of Incorporation in connection with the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Class A Common Stock of the Issuer.
F2 The shares are held of record by Andrew K. Cheng, as Trustee of the Andrew Cheng 2010 Trust UA 10-26-2010.
F3 1/48 of the shares subject to the option vested on July 8, 2017, and 1/48 of the shares vest monthly thereafter.
F4 1/36 of the shares subject to the option vested on February 10, 2020, and 1/36 of the shares vest monthly thereafter.
F5 1/36 of the shares subject to the option vested on January 16, 2021, and 1/36 of the shares vest monthly thereafter.